VICO

A multi-centre randomized open label trial on the safety and efficacy of chloroquine for the treatment of hospitalized adults with laboratory confirmed SARS-CoV-2 infection in Vietnam

This study in Vietnam will evaluate whether chloroquine decreases the SARS-CoV-2 viral load in adults hospitalized with lab-confirmed COVID-19.

Primary objective: To assess if Chloroquine results in a more rapid decline in viral load in throat/nose swabs in patients with COVID-19

Type of study: Phase II trial, therapeutics

Treatment tested: Chloroquine

Countries: Vietnam

Number of sites: 5

Sample size: 240

Study participants: Hospitalized adults with laboratory confirmed SARS-CoV-2 infection

Study status: Recruiting

Principal investigators

  • Dr Vinh Chau, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
  • Prof. Jeremy Day, University of Oxford, UK

More information

 

Last updated: July 2020

 

Disclaimer
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.

Join the coalition
We are looking for individuals and institutions who want to lend their commitment and expertise to fast-track COVID-19 research in low-resource settings
Join us